| Identification | Back Directory | [Name]
PAROXETINE-D4 HCL | [CAS]
110429-35-1 | [Synonyms]
PAROXETINE-D4 HCL
BRL29060A hemihydrate
PAROXETINE HCL HEMIHYDRATE
Paroxetine-D4 hydrochloride
PAROXETINE-D4 HCL USP/EP/BP
PAROXETINE HYDROCHLORIDE 1/2H2O
paroxetine hydrochloride hydrate
PAROXETINE HEMIHYDRATE, EP/BP/USP
Paroxetine Hydrochloride (350 mg)
BRL29060 hydrochloride hemihydrate
aroxetine hydrochloride hemihydrate
PAROXETINE HYDROCHLORIDE HEMIHYDRATE
ParoxetineHydrochlorideHemihydrate>
Paroxetine hydrochloride salt hemihydrate
PAROXETINE-D4 HCL kf-yuwen(at)kf-chem.com
Paroxetine hydrochloride hemihydrate, >=99%
(-)-(3S,4R)-Paroxetine hydrochloride hemihydrate
Paroxetine Hydrochloride (350 mg)G0D0030.972mg/mg(ai)
3-(Benzo[1,3]dioxol-5-yloxymethyl)-4-(4-fluoro-phenyl)-piperidine
PAROXETINE HYDROCHLORIDE HEMIHYDRATE: (+/-)- TRANS-PAROXETINE HYDROCHLORIDE
1,3-benzodioxol-5-yl-[4-(4-fluorophenyl)-3-piperidinyl]methanol hydrochloride
(3S,4R)-(-)-3-[(1,3-Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine Hydrochloride
Paroxetine hydrochloride hemihydrate, 99%, selective serotonin-reuptake inhibitors (SSRIs)
(-)-trans-4-(4-Fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)piperidine hydrochloride hemihydrate
(3S-TRANS)-3-[(1,3-BENZODIOXOL-5-YLOXY)METHYL]-4-(4-FLUOROPHENYL)PIPERIDINE HYDROCHLORIDE HEMIHYDRATE
Piperidine,3-[(1,3-benzodioxol-5-yloxy)Methyl]-4-(4-fluorophenyl)-, hydrochloride, hydrate(2:2:1), (3S,4R)-
Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, hydrochloride, hydrate (2:1), (3S-trans)-
Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, hydrochloride, hydrate (2:1), (3S,4R)- (9CI)
Paroxetine hydrochloride
(3S-trans)-3-[(1,3-Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine hydrochloride | [EINECS(EC#)]
-0 | [Molecular Formula]
C19H17ClD4FNO3 | [MDL Number]
MFCD08064201 | [MOL File]
110429-35-1.mol | [Molecular Weight]
369.85 |
| Chemical Properties | Back Directory | [Appearance]
White or almost white, crystalline powder. | [Melting point ]
121-131 C | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
Slightly soluble in water, freely soluble in methanol, sparingly soluble in ethanol (96 per cent) and in methylene chloride. | [form ]
powder | [color ]
white | [λmax]
292nm(H2O)(lit.) | [Merck ]
14,7043 | [CAS DataBase Reference]
110429-35-1 |
| Hazard Information | Back Directory | [Chemical Properties]
White or almost white, crystalline powder. | [Uses]
Antidepressant;5-HT uptake inhibitor | [General Description]
Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards | [Biochem/physiol Actions]
Paroxetine hydrochloride hemihydrate is one of the most potent and selective of the selective serotonin reuptake inhibitors (SSRI); antidepressant | [in vivo]
Paroxetine treatment obviously attenuates the symptoms of CIA rats. Paroxetine treatment clearly prevents the histological damage of joints and alleviates T cells infiltration into synovial tissue. Paroxetine reveals a strong effect on inhibiting CX3CL1 production in synovial tissues[1]. Paroxetine (20 mg/kg/day) reduces the myocyte cross-sectional area in rat and ROS formation in the remote myocardium. Paroxetine reduces the susceptibility to ventricular tachycardia. Paroxetine treatment following MI decreases LV remodeling and susceptibility to arrhythmias, probably by reducing ROS formation[2]. In CCI paroxetine-treated group, paroxetine (10 mg/kg, i.p.) produces hyperalgesia at days 7 and 10 (P<0.01), but a decrease in pain behavior is seen at day 14. Moreover, paroxetine (10 mg/kg) significantly attenuates tactile hypersensitivity when compared to CCI vehicle-treated group[5]. | [storage]
Store at -20°C |
|
|